ERBB2 and adrenal cortex carcinoma: Moreover, further subgroup analysis of molecular subtypes revealed improved survival in breast-ACC patients with HR+/Her2- compared to breast-IDC patients with HR+/Her2-, whereas survival was similar for ACC-TNBC and IDC-TNBC.